GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in London, United Kingdom. Show more
Location: 79 New Oxford Street, 980 Great West Road, London, WC1A 1DG, United Kingdom | Website: https://www.gsk.com | Industry: Drug Manufacturers - General | Sector: Healthcare
Market Cap
79.91B
52 Wk Range
$31.72 - $44.67
Previous Close
$39.58
Open
$38.70
Volume
6,300,029
Day Range
$38.15 - $38.72
Enterprise Value
170.3B
Cash
4.485B
Avg Qtr Burn
N/A
Insider Ownership
0.06%
Institutional Own.
18.20%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Arexvy Details Viral infection, Respiratory syncytial virus, Vaccine | Approved Quarterly sales | |
Jesduvroq (Daprodustat) Details Chronic kidney disease | Approved Quarterly sales | |
Approved Quarterly sales | ||
Ojjaara (Momelotinib) (JAK Inhibitor) Details Myelofibrosis | Approved Quarterly sales | |
Blujepa (Gepotidacin) Details Urinary tract infection | Approved Quarterly sales | |
Nucala (mepolizumab) Details Chronic obstructive pulmonary disease | Approved Quarterly sales | |
Jemperli (dostarlimab) Details Cancer, Endometrial cancer | Approved Quarterly sales | |
Benlysta (belimumab) Details Systemic lupus erythematosus | Approved Quarterly sales | |
Jemperli (dostarlimab) Details Endometrial cancer, Cancer | Approved Quarterly sales | |
Depemokimab Details Chronic rhinosinusitis with nasal polyps | Phase 3 Data readout | |
Linerixibat Details Primary biliary cholangitis | Phase 3 Data readout | |
BLU-5937 (P2X3 antagonist) Details Chronic cough | Phase 3 Data readout | |
Bepirovirsen Details Hepatitis B vaccine | Phase 3 Data readout | |
Blenrep (belantamab mafodotin) + BorDex Details Multiple myeloma | Phase 3 Data readout | |
Zejula Details Ovarian cancer, Solid tumor/s, Cancer, Platinum-resistant ovarian cancer | Phase 3 Data readout | |
Zejula Details Solid tumor/s, Cancer, Non-small cell lung carcinoma, Lung cancer | Phase 3 Data readout | |
Cobolimab Details Solid tumor/s, Non-small cell lung carcinoma, Cancer, Lung cancer | Phase 3 Data readout | |
Gepotidacin Details Prevention of gonorrhea | Phase 3 Update | |
Depemokimab Details Asthma | Phase 3 Update |